Literature DB >> 17507662

Hot spots of retroviral integration in human CD34+ hematopoietic cells.

Claudia Cattoglio1, Giulia Facchini, Daniela Sartori, Antonella Antonelli, Annarita Miccio, Barbara Cassani, Manfred Schmidt, Christof von Kalle, Steve Howe, Adrian J Thrasher, Alessandro Aiuti, Giuliana Ferrari, Alessandra Recchia, Fulvio Mavilio.   

Abstract

Insertional oncogenesis is a possible consequence of the integration of gamma-retroviral (RV) or lentiviral (LV) vectors into the human genome. RV common insertion sites (CISs) have been identified in hematopoietic malignancies and in the nonmalignant progeny of transduced hematopoietic stem/progenitor cells (HSCs), possibly as a consequence of clonal selection in vivo. We have mapped a large number of RV and LV integrations in human CD34(+) HSCs, transduced in vitro and analyzed without selection. Recurrent insertion sites (hot spots) account for more than 21% of the RV integration events, while they are significantly less frequent in the case of LV vectors. RV but not LV hot spots are highly enriched in proto-oncogenes, cancer-associated CISs, and growth-controlling genes, indicating that at least part of the biases observed in the HSC progeny in vivo are characteristics of RV integration, already present in nontransplanted cells. Genes involved in hematopoietic and immune system development are targeted at high frequency and enriched in hot spots, suggesting that the CD34(+) gene expression program is instrumental in directing RV integration. The lower propensity of LV vectors for integrating in potentially dangerous regions of the human genome may be a factor determining a better safety profile for gene therapy applications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507662     DOI: 10.1182/blood-2007-01-068759

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  119 in total

Review 1.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

2.  Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts.

Authors:  Arianna Moiani; Ylenia Paleari; Daniela Sartori; Riccardo Mezzadra; Annarita Miccio; Claudia Cattoglio; Fabienne Cocchiarella; Maria Rosa Lidonnici; Giuliana Ferrari; Fulvio Mavilio
Journal:  J Clin Invest       Date:  2012-04-23       Impact factor: 14.808

3.  Retroviral infection of hES cells produces random-like integration patterns.

Authors:  Kwang-il Lim
Journal:  Mol Cells       Date:  2012-04-20       Impact factor: 5.034

Review 4.  Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.

Authors:  Megan D Hoban; Stuart H Orkin; Daniel E Bauer
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

5.  Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

Authors:  Sid P Kerkar; Luis Sanchez-Perez; Shicheng Yang; Zachary A Borman; Pawel Muranski; Yun Ji; Dhanalakshmi Chinnasamy; Andrew D M Kaiser; Christian S Hinrichs; Christopher A Klebanoff; Christopher D Scott; Luca Gattinoni; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

6.  Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.

Authors:  Giorgia Santilli; Elena Almarza; Christian Brendel; Uimook Choi; Chiara Beilin; Michael P Blundell; Sneha Haria; Kathryn L Parsley; Christine Kinnon; Harry L Malech; Juan A Bueren; Manuel Grez; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

7.  Preventing and exploiting the oncogenic potential of integrating gene vectors.

Authors:  Ute Modlich; Christopher Baum
Journal:  J Clin Invest       Date:  2009-04       Impact factor: 14.808

8.  Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design.

Authors:  Giulietta Maruggi; Simona Porcellini; Giulia Facchini; Serena K Perna; Claudia Cattoglio; Daniela Sartori; Alessandro Ambrosi; Axel Schambach; Christopher Baum; Chiara Bonini; Chiara Bovolenta; Fulvio Mavilio; Alessandra Recchia
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

9.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

Review 10.  Gene-delivery systems for iPS cell generation.

Authors:  Lijian Shao; Wen-Shu Wu
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.